A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 17, Issue 2, 1997, Pages 239-245

  Wild, Sarah H ^a   Fortmann, Stephen P ^a   Marcovina, Santica M ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

apo(a) isoforms; coronary artery disease; Lp(a) values; risk factors

Indexed keywords

LIPOPROTEIN A;

ADOLESCENT; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY RISK; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; SEX DIFFERENCE;

EID: 0031037779     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.17.2.239     Document Type: Article

References (29)

1. Marcovina SM, Morrisett JD. Structure and metabolism of lipoprotein(a). Curr Opin Lipidol 1995;6:136-145.
2. Lackner C, Cohen JC, Hobbs HH. Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum Mol Genet. 1993;2:933-940.
3. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987;330:132-137.
4. Marcovina SM, Zhang ZH, Gaur VP, Albers JJ. Identification of 34 apolipoprotein(a) isoforms: differential expression of apolipoprotein(a) alleles between American blacks and whites. Biochem Biophys Res Commun. 1993;191:1192-1196.
5. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 1992;90:52-60.
6. Utermann G. The mysteries of lipoprotein(a). Science. 1989;246:904-910.
7. Marcovina SM, Levine DM, Lippi G. Lipoprotein(a): structure, measurement, and clinical significance. In: Rifai N, Warnick R, eds. Laboratory Measurement of Lipids, Lipoproteins, and Apolipoproteins. Washington, DC: AACC Press; 1994:235-263.
8. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein(a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. Br Med J. 1990;301:1248-1251.
9. Sigurdsson G, Baldursdottir A, Sigvaldason H, Agnarsson U, Thorgeirsson G, Sigfusson N. Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol. 1992;69:1251-1254.
10. Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis CE, Abolafia JM, Lippel K, Levy RI. Lipoprotein(a) levels and risk of coronary heart disease in men: the Lipid Research Clinics Coronary Primary Prevention Trial. JAMA. 1994;271:999-1003.
11. Cremer P, Nagel D, Labrot B, Mann H, Muche R, Elster H, Seidel D. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Gottingen Risk, Incidence and Prevalence Study (GRIPS). Eur J Clin Invest. 1994;24:444-453.
12. Jauhiainen M, Koskinen P, Ehnholm C, Frick HM, Manttari M, Manninen V, Huttunen JK. Lipoprotein(a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis. 1991 ;85:59-67.
13. Ridker PM, Hennekens CH, Stampfer MJ. Prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA. 1993;270:2195-2199.
14. Alfthan G, Pekkanen J, Jauhiainen M, Pitkdniemi J, Karvonen M, Tuomilehto J, Salonen JT, Ehnholm C. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 1994;106:9-19.
15. Marcovina SM, Albers JJ, Gabel B, Koschinsky ML, Gaur VP. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem. 1995;41:246-255.
16. Farquhar JW, Fortmann SP, Maccoby N, Haskell WL, Williams PT, Flora JA, Taylor CB, Brown BW Jr, Solomon DS, Hulley SB. The Stanford Five City Project: design and methods. Am J Epidemiol. 1985;122:323-334.
17. Farquhar JW, Fortmann SP, Flora JA, Taylor CB, Haskell WL, Maccoby N, Wood PD. Effects of community wide education on cardiovascular disease risk factors: the Stanford Five-City Project: JAMA. 1990;264:359-365.
18. Fortmann SP, Haskell WL, Williams PT, Varady AN, Hulley SB, Farquhar JW. Community surveillance of cardiovascular diseases in the Stanford Five City Project. Am J Epidemiol. 1986;123:656-669.
19. The Lipid Research Clinics Program Manual of Laboratory Operations, Lipid and Lipoprotein Analysis. 2nd ed. Washington, DC: US Department of Health and Human Services; 1982. (Originally published as US Dept of Health, Education, and Welfare publication NIH 75-628.)
20. Kamboh MI, Ferrell RE, Kottke BA. Expressed hypervariable polymorphism of apolipoprotein(a). Am J Hum Genet. 1991;49:1063-1074.
21. Lackner C, Boerwinkle E, Leffert CC, Rahmig T, Hobbs HH. Molecular basis of apolipoprotein(a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J Clin Invest. 1991;41:246-255.
22. Marcovina SM, Hobbs HH, Albers JJ. Relation between number of apolipoprotein(a) kringle 4 repeats and mobility of isoforms in agarose gel: bases for a standardized isoform nomenclature. Clin Chem. 1996;42:436-439.
23. Warnick GR, Benderson J, Albers J. Dextran sulfate-Mg++ precipitation procedure for quantitation of high density lipoprotein cholesterol. Clin. Chem. 1982;28:1379-1388.
24. Fortmann SP, Marcuson R, Bitter PH, Haskell WL. A comparison of the Sphygmetrics SR-2 automatic blood pressure recorder to the mercury sphygmomanometer in population studies. Am J Epidemiol. 1981;114:836-844.
25. Marcovina SM, Gaur VP, Albers JJ. Biological variability of cholesterol, triglyceride, LDL and HDL cholesterol, lipoprotein(a), apolipoproteins A-I and B. Clin Chem. 1994;40:574-578.
26. Kraemer HC. Evaluating Medical Tests: Objective and Quantitative Guidelines. Newbury Park, Calif: Sage Publications, Inc; 1992.
27. Boston AG, Gagnon DR, Cupples A, Wilson PWF. Jenner JL, Ordovas JM, Schaefer EJ, Castelli WP. A prospective investigation of elevated lipoprotein(a) detected by electrophoresis and cardiovascular disease in women: the Framingham Heart Study. Circulation. 1994;90:1688-1695.
28. Boston AG, Cupples LA, Jenner JL, Ordovas JM, Seman U, Wilson PWF, Schaefer EJ, Castelli WP. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. JAMA. 1996;276:544-548.
29. Maher VMG, Brown BG, Marcovina SM, Hilger LA, Zhao X-Q, Albers JJ. Effects of lowering LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA. 1995;274:19-23.